KZR
Kezar Life Sciences Inc.
Company Overview
| Mkt Cap | $54.25M | Price | $7.31 |
| Volume | 13.46K | Change | +0.27% |
| P/E Ratio | -0.6 | Open | $7.32 |
| Revenue | -- | Prev Close | $7.29 |
| Net Income | $-83.7M | 52W Range | $3.53 - $7.55 |
| Div Yield | N/A | Target | $6.00 |
| Overall | 48 | Value | 60 |
| Quality | 23 | Technical | 63 |
No chart data available
About Kezar Life Sciences Inc.
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Latest News
Kalamazoo advances Ashburton drilling, raises A$12.1m and names new CEO
Kalamazoo Resources Boosts Cash Reserves Through Equity Funding Amid Exploration Spend
MacKenzie Realty Declares Quarterly Preferred Share Dividends
Kezar Life Sciences Announces Major Executive Leadership Changes
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Aura Biosciences Inc (AURA) and Kezar Life Sciences (KZR)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | KZR | $7.31 | +0.3% | 13.46K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Kezar Life Sciences Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW